UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/715,998	11/18/2003	Scott R. Presnell	98-55D2	5205

10117 7590 01/24/2007

ZYMOGENETICS, INC.
INTELLECTUAL PROPERTY DEPARTMENT
1201 EASTLAKE AVENUE EAST
SEATTLE, WA 98102-3702

EXAMINER	
SEHARASEYON, JEGATHEESAN	
ART UNIT	**PAPER NUMBER**
1647	

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	01/24/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No.	Applicant(s)	
	10/715,998	PRESNELL ET AL.	
	Examiner	Art Unit	
	Jegatheesan Seharaseyon, Ph.D	1647	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *03 November 2006*.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-45* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1-45* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☒ The specification is objected to by the Examiner.

10)☒ The drawing(s) filed on *18 November 2003* is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date *11/18/2003*.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

DETAILED ACTION

1. Applicant's election without traverse of the species (k), directed to an immunoglobulin Fc domain fusion protein in the reply filed on 11/03/2006 is acknowledged. Claims 1-45 are pending and under consideration.

Priority

2. Applicant's claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) as follows: This application is claiming the benefit of prior-filed non provisional application Nos. 60/100, 896, 60/123, 546 and 60/142, 574 under 35 U.S.C. 119(e). Copendency between the current application and the prior application is required. Since the applications are not copending, the benefit claim to the prior-filed non-provisional application is improper. Applicant is required to delete the reference to the prior-filed application from the first sentence(s) of the specification, or the application data sheet, depending on where the reference was originally submitted, unless applicant can establish copendency between the applications.

3. This application appears to be a division of Application No. 09/404, 641, filed September 23, 1999. A later application for a distinct or independent invention, carved out of a pending application and disclosing and claiming only subject matter disclosed in an earlier or parent application is known as a divisional application or "division." The divisional application should set forth the portion of the earlier disclosure that is germane to the invention as claimed in the divisional application.

4. Applicant is required to update the current status of 10/414, 186 in the first paragraph of the Application.

Drawings

5. The drawings filed 11/18/2003 are acknowledged.

Information Disclosure Statement

6. The IDS submitted 11/18/2003 has been considered.

Specification

7. The use of the trademark human Multiple Tissue Northern Blots (p.76), QiaexII (p. 76), glutaMax (p.80), ElectroMAX (p.80), Qiaquick (p.82), Expresshyb (p.114) and Hybond-N (p.114) etc. have been noted in this application. They should be capitalized wherever they appear and be accompanied by the generic terminology.

Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner, which might adversely affect their validity as trademarks.

8. The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code (see p. 74 and 78). Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

Claim Objections

9. Claims 1, 3, 12, 22, 23, 24 and 39 are objected to because of the following informalities: It is suggested that the claim be rewritten to better clarify the invention.

9a. In claim 1, "An isolated polynucleotide encoding a polypeptide consisting of a sequence of amino acid residues selected from...." rewritten as "An isolated polynucleotide encoding a polypeptide consisting of a sequence selected from...."

9b. In claim 3, "An isolated polynucleotide encoding a polypeptide consisting of a sequence of amino acid residues selected from...." rewritten as "An isolated polynucleotide encoding a polypeptide consisting of a sequence selected from...."

9c. In claim 12, "An isolated polynucleotide encoding a polypeptide consisting of a sequence of amino acid residues selected from...." rewritten as "An isolated polynucleotide encoding a polypeptide consisting of a sequence selected from...."

9d. In claim 22, "An isolated polynucleotide comprising a sequence of polynucleotides selected from...." rewritten as "An isolated polynucleotide comprising of a sequence selected from...."

9e. In claim 23, "The isolated polynucleotide according to claim 22, wherein the polynucleotide consists of a sequence of polynucleotides selected from...." rewritten as "The isolated polynucleotide according to claim 22, wherein the polynucleotide consists of a sequence selected from."

9f. In claim 24, "An isolated polynucleotide consists of a sequence of polynucleotides that is selected from...." rewritten as "An isolated polynucleotide consists of a sequence that is selected from...."

9g. In claim 39, "A DNA construct encoding a fusion protein, the DNA construct comprising: a first DNA segment encoding a polypeptide consisting of a sequence of amino acid residues selected from..." re written as "A DNA construct encoding a fusion protein, the DNA construct comprising: a first DNA segment encoding a polypeptide consisting of a sequence selected from...".

Appropriate correction is required.

Claim Rejections - 35 USC § 112

10. The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

10a. Claims 1-45 are rejected under 35 U.S.C. 112, first paragraph, because the specification while enabling for polynucleotide sequence of SEQ ID NO: 1 or polynucleotide sequence of SEQ IDNO: 1 from nucleotide 1 to nucleotide 1682 or polynucleotide sequence of SEQ IDNO: 1 from nucleotide 1 to nucleotide 779 or polynucleotide sequence of SEQ IDNO: 1 from nucleotide 1 to nucleotide 833 or polynucleotide sequence of SEQ IDNO: 1 from nucleotide 1 to nucleotide 2887 or polynucleotide sequence of SEQ IDNO: 834 from nucleotide 1 to nucleotide 2887 polynucleotide sequence of SEQ IDNO: 1 from nucleotide 126 to nucleotide 779 or

polynucleotide sequence of SEQ IDNO: 1 from nucleotide 126 to nucleotide 833 or polynucleotide sequence of SEQ IDNO: 1 from nucleotide 834 to nucleotide 1682 or polynucleotide sequence of SEQ IDNO: 1 from nucleotide 126 to nucleotide 1682 or nucleotide sequence encoding SEQ ID NO: 2 from amino acid 20 to amino acid 237 or nucleotide sequence encoding SEQ ID NO: 2 from amino acid 20 to amino acid 255 or nucleotide sequence encoding SEQ ID NO: 2 from amino acid 256 to amino acid 538 or nucleotide sequence encoding SEQ ID NO: 2 from amino acid 20 to amino acid 538 or polynucleotide sequences complementary, does not reasonably provide enablement for all possible nucleotide fragments contemplated by the Applicant. The claims also recite the phrases "a polynucleotide sequence" and " a polypeptide " and thus, are broadly interpreted by the Examiner as reading upon: (i) fragments of SEQ ID NOs: 1-2, including sequences only 10 amino acids or 60 nucleic acids in length (see specification page 12 and page 23). The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention as claimed.

The test of enablement is not whether any experimentation is necessary, but whether, if experimentation is necessary, it is undue. See *In re Wands,* 858 F.2d at 737, 8 USPQ2d at 1404. The factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue" include, but are not limited to: (1) the breadth of the claims; (2) the nature of the invention; (3) the state of the prior art; (4) the level of one of ordinary skill; (5) the level

of predictability in the art; (6) the amount of direction provided by the inventor; (7) the existence of working examples; and (8) the quantity of experimentation needed to make or use the invention based on the content of the disclosure.

The instant claims reads on polynucleotide sequence fragments of SEQ ID NO: 1 and polynucleotides encoding SEQ ID NO: 2. The claims recite the phrases "a polynucleotide sequence" and " a polypeptide " and thus, are broadly interpreted by the Examiner as reading upon: (i) fragments of SEQ ID NOs: 1-2, including sequences only 10 amino acids or 60 nucleic acids in length (see specification page 12 and page 23). In addition, Applicant has not defined in the specification if " complementary" describes a full-length complementary sequence and thus the Examiner has interpreted it to include fragments that are at least 60 nucleic acids long.

However, other than the nucleic acid sequence of SEQ ID NO: 1, nucleic acid encoding polypeptide of SEQ ID NO: 2, the specific fragments of the polynucleotide sequence of SEQ ID NO: 1 and polynucleotide sequence encoding SEQ ID NO: 2 disclosed in the instant claims, the specification as filed fails to disclose any other sequence contemplated in the instant claim such as "a polynucleotide sequence" and " a polypeptide". The specification does not teach functional or structural characteristics of the polynucleotide and polypeptide fragments encompassed by the claims.

Despite knowledge in the art for producing variant polynucleotide that encode polypeptides, the specification fails to provide any guidance regarding the variant polynucleotide sequences encoding the polypeptides by the contemplated methods that retain the function. Furthermore, detailed information regarding the structural and

functional requirements of the disclosed protein is lacking. Although it is accepted that the amino acid sequence of a polypeptide determines its structural and functional properties, predicting a protein's structure and function from mere sequence data remains an elusive task. The problem of predicting protein structure from sequence data and in turn utilizing predicted structural determinations to ascertain functional aspects of the protein is extremely complex. While it is known that many amino acid substitutions are generally possible in any given protein the positions within the protein's sequence where such amino acid substitutions can be made with a reasonable expectation of success are limited. Certain positions in the sequence are critical to the protein's structure/function relationship, e.g. such as various sites or regions directly involved in binding, activity and in providing the correct three-dimensional spatial orientation of binding and active sites. These or other regions may also be critical determinants of antigenicity. These regions can tolerate only relatively conservative substitutions or no substitutions (see Wells, 1990, Biochemistry 29:8509-8517; Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495). However, Applicant has provided little or no guidance beyond the mere presentation of sequence data to enable one of ordinary skill in the art to determine, without undue experimentation, the positions in the protein which are tolerant to change (e.g. such as by amino acid substitutions or deletions), and the nature and extent of changes that can be made in these positions. Although the specification outlines art-recognized procedures for producing and screening for active variants, this is not adequate guidance as to the nature of active derivatives that may be constructed, but is merely an

invitation to the artisan to use the current invention as a starting point for further experimentation. Even if an active or binding site were identified in the specification, they may not be sufficient, as the ordinary artisan would immediately recognize that an active or binding site must assume the proper three-dimensional configuration to be active, which conformation is dependent upon surrounding residues; therefore substitution of non-essential residues can often destroy activity. Therefore, predicting which polypeptide, if any, would retain the functions of the protein is well outside the realm of routine experimentation. Further, since no function has been attributed to the claimed protein, the skilled artisan would not know what function to test for. Thus, an undue amount of experimentation would be required to generate the changes/modifications contemplated and yet retain the function of the proteins claimed.

Applicant has not taught how one of skill in the art would use the full scope of polynucleotide sequences encompassed by the invention of claims 1-45. The specification as filed does not sufficiently teach one of skill in the art how to make and/or use the full scope of the claimed sequences. The amount of experimentation required to make and/or use the full scope of the claimed sequences would require trial and error experimentation to determine the functional sequences.

Given the breadth of claims 1-45 in light of the unpredictability of the art as determined by the lack of working examples and shown by the prior at of record, the level of skill of the artisan, and the lack of guidance provided in the instant specification, it would require undue experimentation for one of ordinary skill in the art to make and

use the claimed invention. Claims 26-29, 31-38 and 40-45 are rejected insofar as they are dependent on rejected claims 25, 30 and 39.

10b. Claims 1-45 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. *This is a written description rejection.*

The specification discloses the polynucleotide sequence of SEQ ID NO: 1, polynucleotide sequence encoding SEQ ID NO: 2, the specific fragments of the polynucleotide sequence of SEQ ID NO: 1 and polynucleotide sequence encoding SEQ ID NO: 2 disclosed in the claims. This meets the written description provisions of 35 USC 112, first paragraph. However, the specification does not disclose all possible polynucleotide fragments of SEQ ID NO: 1 and fragments of polynucleotides encoding SEQ ID NO: 2 contemplated by the Applicant. The claims recite the phrases "a polynucleotide sequence" and " a polypeptide " and thus, are broadly interpreted by the Examiner as reading upon: (i) fragments of SEQ ID NOs: 1-2, including sequences only 10 amino acids or 60 nucleic acids in length (see specification page 12 and page 23). In addition, Applicant has not defined in the specification if " complementary" describes a full-length complementary sequence and thus the Examiner has interpreted it to include fragments that are at least 60 nucleic acids long.

The claims as written, however, encompass variant sequences which were not originally contemplated and fail to meet the written description provision of 35 USC 112, first paragraph because the written description is not commensurate in scope with the recitation of claims 1-45. The specification does not provide written description to support the genus encompassed by the instant claims.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession *of the invention*. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed*." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed" (*See Vas-Cath* at page 1116).

With the exception of the nucleic acid sequence of SEQ ID NO: 1, nucleic acid encoding polypeptide of SEQ ID NO: 2, the specific fragments of the polynucleotide sequence of SEQ ID NO: 1 and polynucleotide sequence encoding SEQ ID NO: 2 disclosed in the instant claims, the specification as filed fails to disclose any other sequence contemplated in the instant claim such as "a polynucleotide sequence" and " a polypeptide". Thus, the skilled artisan cannot envision all the detailed chemical structure of the claimed polynucleotide sequences regardless of the complexity or simplicity of the method of isolation.

Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. The polypeptide itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016. One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481, 1483. In *Fiddes v. Baird*, claims directed to mammalian FGF's were found unpatentable due to lack of written description for the broad class.

Therefore, only the nucleic acid sequence of SEQ ID NO: 1, nucleic acid encoding polypeptide of SEQ ID NO: 2, the specific fragments of the polynucleotide

sequence of SEQ ID NO: 1 and polynucleotide sequence encoding SEQ ID NO: 2 disclosed in the instant claims, but not the full breadth of the claims meets the written description provision of 35 USC 112, first paragraph. The species specifically disclosed are not representative of the genus because the genus is highly variant. As a result, it does not appear that the inventors were in possession of various polynucleotide sequences set forth in claims 1-45. Claims 26-29, 31-38 and 40-45 are rejected insofar as they are dependent on rejected claims 25, 30 and 39.

Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 USC 112 is severable from its enablement provision. (See page 1115.) Applicants are directed to the Revised Interim Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, ¶ 1 "Written Description" Requirement, Federal Register, Vol. 64, No. 244, pages 71427-71440, Tuesday December 21, 1999.

Claim Rejections - 35 USC § 102

11. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000.

Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

11a. Claims 1-45 are rejected under 35 U.S.C. 102(e) as being anticipated by Donaldson et al. (U. S. Patent No. 6, 057, 128, PTO1449 of 11/18/2003).

Claims are drawn to isolated nucleic acids, vectors, host cells and a method of producing a polypeptide. The claims recite the phrases "a polynucleotide sequence" and " a polypeptide " and thus, are broadly interpreted by the Examiner as reading upon: (i) fragments of SEQ ID NOs: 1-2, including sequences only 10 amino acids or 60 nucleic acids in length (see specification page 12 and page 23). In addition, Applicant has not defined in the specification if " complementary" describes a full-length complementary sequence and thus the Examiner has interpreted it to include fragments that are at least 60 nucleic acids long.

Donaldson et al. discloses polynucleotide sequence (SEQ ID NO: 1) that has 100% identity to SEQ ID NO: 1 from nt 51-2475 of the instant invention (see Appendix A1-A5). Further, it also discloses nucleotides encoding SEQ ID NO: 2 has greater than 99.9% identity to nucleotides 103-1602 of SEQ ID NO: 1 of the instant invention (see Appendix B1-4). Thus, the reference anticipates the various variants and fragments of the instant invention. The functional activities recited in the instant claims are inherent to the polypeptide. The fusion protein comprises an antibody fragment, such as an Fc fragment (column 2, lines 32-33). Donaldson et al. vectors, host cells and a method of making the protein (column 4). Therefore, claims 1-45 are rejected as being anticipated by Donaldson et al. (U. S. Patent No. 6, 057, 128, PTO1449 of 11/18/2003).

11b. Claims 1-45 are rejected under 35 U.S.C. 102(e) as being anticipated by Presnell et al. (U. S. Patent No. 6, 576, 744).

Claims are drawn to isolated nucleic acids, vectors, host cells and a method of producing a polypeptide. The claims recite the phrases "a polynucleotide sequence" and " a polypeptide " and thus, are broadly interpreted by the Examiner as reading upon: (i) fragments of SEQ ID NOs: 1-2, including sequences only 10 amino acids or 60 nucleic acids in length (see specification page 12 and page 23). In addition, Applicant has not defined in the specification if " complementary" describes a full-length complementary sequence and thus the Examiner has interpreted it to include fragments that are at least 60 nucleic acids long.

Presnell et al. teach polynucleotide of SEQ ID NO: 1, polypeptide of SEQ ID NO: 2. The reference also discloses various nucleotide fragments encoded by SEQ ID NO: 2 contemplated by the instant invention (see columns 2-5, 10 and claims) and fusion proteins with the various activities. Presenell et al. vectors, host cells and a method of making the protein (columns 25-30). Therefore, claims 1-45 are rejected as being anticipated by Presnell et al. (U. S. Patent No. 6, 576, 744).

Double Patenting

12. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir.

1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

12a.Claims 1-21 and 25-45 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-36 of copending Application No. 11/537, 874. Although the conflicting claims are not identical, they are not patentably distinct from each other because WSXWS is within SEQ ID NO: 2. Further art recognizes that mannosylation occurs at Trp residues of WSXWS motifs.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

12b.Claims 1-21 and 25-45 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-7 of copending Application No. 11/537, 879. Although the conflicting claims are not identical, they are not patentably distinct from each other because WSXWS is within SEQ ID NO: 2. Further art recognizes that mannosylation occurs at Trp residues of WSXWS motifs.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

13. No claims are allowable.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jegatheesan Seharaseyon, Ph.D whose telephone number is 571-272-0892. The examiner can normally be reached on M-F: 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

JS
Art Unit 1647
January 18, 2007

CHRISTINE J. SAOUD
PRIMARY EXAMINER

Christine J. Saoud

Appendix A1 Applicant's Copy

SCORE Search Results Details for Application 1(and Search Result $itemName.

This page gives you Search Results detail for the Application 10715998 and Search Result $itemNa
start | next page

Go Bi

```
                    Qy       2579 GGTTTCCAGGCTTAAAATCAGTCCGTTTCGTCTCTTGGAAACAGCTC
                         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2581 GGTTTCCAGGCTTAAAATCAGTCCGTTTCGTCTCTTGGAAACAGCTCCCCACCAACCAAG 2640

Qy       2639 ATTTCTTTTTCTAACTTCTGCTACTAAGTTTTTAAAAATTCCCTTTATGCACCCAAGAGA 2698
                         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2641 ATTTCTTTTTCTAACTTCTGCTACTAAGTTTTTAAAAATTCCCTTTATGCACCCAAGAGA 2700

Qy       2699 TATTTATTAAACACCAATTACGTAGCAGGCCATGGCTCATGGGACCCACCCCCCGTGGCA 2758
                         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2701 TATTTATTAAACACCAATTACGTAGCAGGCCATGGCTCATGGGACCCACCCCCCGTGGCA 2760

Qy       2759 CTCATGGAGGGGGCTGCAGGTTGGAACTATGCAGTGTGCTCCGGCCACACATCCTGCTGG 2818
                         |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||
Db       2761 CTCATGGAGGGGGGTGCAGGTTGGAACTATGCAGTGTGCTCCGGCCACACATCCTGCTGG 2820

Qy       2819 GCCCCCTACCCTGCCCCAATTCAATCCTGCCAATAAATCCTGTCTTATTTGTTCATCCTG 2878
                         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2821 GCCCCCTACCCTGCCCCAATTCAATCCTGCCAATAAATCCTGTCTTATTTGTTCATCCTG 2880

Qy       2879 GAGAATTGA 2887
                         |||||||||
Db       2881 GAGAATTGA 2889
```

```
RESULT 5
US-09-040-005-1
; Sequence 1, Application US/09040005
; Patent No. 6057128
;  GENERAL INFORMATION:
;    APPLICANT:  Donaldson, Debra
;    APPLICANT:  Unger, Michelle
;    TITLE OF INVENTION:  MU-1 RECEPTOR
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Genetics Institute, Inc.
;      STREET:  87 CmabridgePark Drive
;      CITY:  Cambridge
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02140
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/040,005
;      FILING DATE:
```

Appendix A2 Applicants copy

```
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Brown, Scott A
;      REGISTRATION NUMBER:  32,724
;      REFERENCE/DOCKET NUMBER:  GI5320
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-498-8224
;      TELEFAX:  617-876-5851
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  2665 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-09-040-005-1

  Query Match             84.0%;  Score 2425;  DB 3;  Length 2665;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 2425;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          51 AGGCCCGTGGGAGTCAGCATGCCGCGTGGCTGGGCCGCCCCCTTGCTCCTGCTGCTGCTC 110
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         218 AGGCCCGTGGGAGTCAGCATGCCGCGTGGCTGGGCCGCCCCCTTGCTCCTGCTGCTGCTC 277

Qy         111 CAGGGAGGCTGGGGCTGCCCCGACCTCGTCTGCTACACCGATTACCTCCAGACGGTCATC 170
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         278 CAGGGAGGCTGGGGCTGCCCCGACCTCGTCTGCTACACCGATTACCTCCAGACGGTCATC 337

Qy         171 TGCATCCTGGAAATGTGGAACCTCCACCCCAGCACGCTCACCCTTACCTGGCAAGACCAG 230
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         338 TGCATCCTGGAAATGTGGAACCTCCACCCCAGCACGCTCACCCTTACCTGGCAAGACCAG 397

Qy         231 TATGAAGAGCTGAAGGACGAGGCCACCTCCTGCAGCCTCCACAGGTCGGCCCACAATGCC 290
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         398 TATGAAGAGCTGAAGGACGAGGCCACCTCCTGCAGCCTCCACAGGTCGGCCCACAATGCC 457

Qy         291 ACGCATGCCACCTACACCTGCCACATGGATGTATTCCACTTCATGGCCGACGACATTTTC 350
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         458 ACGCATGCCACCTACACCTGCCACATGGATGTATTCCACTTCATGGCCGACGACATTTTC 517

Qy         351 AGTGTCAACATCACAGACCAGTCTGGCAACTACTCCCAGGAGTGTGGCAGCTTTCTCCTG 410
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         518 AGTGTCAACATCACAGACCAGTCTGGCAACTACTCCCAGGAGTGTGGCAGCTTTCTCCTG 577

Qy         411 GCTGAGAGCATCAAGCCGGCTCCCCCTTTCAACGTGACTGTGACCTTCTCAGGACAGTAT 470
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         578 GCTGAGAGCATCAAGCCGGCTCCCCCTTTCAACGTGACTGTGACCTTCTCAGGACAGTAT 637

Qy         471 AATATCTCCTGGCGCTCAGATTACGAAGACCCTGCCTTCTACATGCTGAAGGGCAAGCTT 530
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         638 AATATCTCCTGGCGCTCAGATTACGAAGACCCTGCCTTCTACATGCTGAAGGGCAAGCTT 697

Qy         531 CAGTATGAGCTGCAGTACAGGAACCGGGGAGACCCCTGGGCTGTGAGTCCGAGGAGAAAG 590
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         698 CAGTATGAGCTGCAGTACAGGAACCGGGGAGACCCCTGGGCTGTGAGTCCGAGGAGAAAG 757

Qy         591 CTGATCTCAGTGGACTCAAGAAGTGTCTCCCTCCTCCCCCTGGAGTTCCGCAAAGACTCG 650
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         758 CTGATCTCAGTGGACTCAAGAAGTGTCTCCCTCCTCCCCCTGGAGTTCCGCAAAGACTCG 817
```

Appendix A3 Applicants copy

```
Qy       651 AGCTATGAGCTGCAGGTGCGGGCAGGGCCCATGCCTGGCTCCTCCTACCAGGGGACCTGG 710
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       818 AGCTATGAGCTGCAGGTGCGGGCAGGGCCCATGCCTGGCTCCTCCTACCAGGGGACCTGG 877

Qy       711 AGTGAATGGAGTGACCCGGTCATCTTTCAGACCCAGTCAGAGGAGTTAAAGGAAGGCTGG 770
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       878 AGTGAATGGAGTGACCCGGTCATCTTTCAGACCCAGTCAGAGGAGTTAAAGGAAGGCTGG 937

Qy       771 AACCCTCACCTGCTGCTTCTCCTCCTGCTTGTCATAGTCTTCATTCCTGCCTTCTGGAGC 830
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       938 AACCCTCACCTGCTGCTTCTCCTCCTGCTTGTCATAGTCTTCATTCCTGCCTTCTGGAGC 997

Qy       831 CTGAAGACCCATCCATTGTGGAGGCTATGGAAGAAGATATGGGCCGTCCCCAGCCCTGAG 890
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       998 CTGAAGACCCATCCATTGTGGAGGCTATGGAAGAAGATATGGGCCGTCCCCAGCCCTGAG 1057

Qy       891 CGGTTCTTCATGCCCCTGTACAAGGGCTGCAGCGGAGACTTCAAGAAATGGGTGGGTGCA 950
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1058 CGGTTCTTCATGCCCCTGTACAAGGGCTGCAGCGGAGACTTCAAGAAATGGGTGGGTGCA 1117

Qy       951 CCCTTCACTGGCTCCAGCCTGGAGCTGGGACCCTGGAGCCCAGAGGTGCCCTCCACCCTG 1010
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1118 CCCTTCACTGGCTCCAGCCTGGAGCTGGGACCCTGGAGCCCAGAGGTGCCCTCCACCCTG 1177

Qy      1011 GAGGTGTACAGCTGCCACCCACCACGGAGCCCGGCCAAGAGGCTGCAGCTCACGGAGCTA 1070
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1178 GAGGTGTACAGCTGCCACCCACCACGGAGCCCGGCCAAGAGGCTGCAGCTCACGGAGCTA 1237

Qy      1071 CAAGAACCAGCAGAGCTGGTGGAGTCTGACGGTGTGCCCAAGCCCAGCTTCTGGCCGACA 1130
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1238 CAAGAACCAGCAGAGCTGGTGGAGTCTGACGGTGTGCCCAAGCCCAGCTTCTGGCCGACA 1297

Qy      1131 GCCCAGAACTCGGGGGGCTCAGCTTACAGTGAGGAGAGGGATCGGCCATACGGCCTGGTG 1190
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1298 GCCCAGAACTCGGGGGGCTCAGCTTACAGTGAGGAGAGGGATCGGCCATACGGCCTGGTG 1357

Qy      1191 TCCATTGACACAGTGACTGTGCTAGATGCAGAGGGGCCATGCACCTGGCCCTGCAGCTGT 1250
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1358 TCCATTGACACAGTGACTGTGCTAGATGCAGAGGGGCCATGCACCTGGCCCTGCAGCTGT 1417

Qy      1251 GAGGATGACGGCTACCCAGCCCTGGACCTGGATGCTGGCCTGGAGCCCAGCCCAGGCCTA 1310
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1418 GAGGATGACGGCTACCCAGCCCTGGACCTGGATGCTGGCCTGGAGCCCAGCCCAGGCCTA 1477

Qy      1311 GAGGACCCACTCTTGGATGCAGGGACCACAGTCCTGTCCTGTGGCTGTGTCTCAGCTGGC 1370
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1478 GAGGACCCACTCTTGGATGCAGGGACCACAGTCCTGTCCTGTGGCTGTGTCTCAGCTGGC 1537

Qy      1371 AGCCCTGGGCTAGGAGGGCCCCTGGGAAGCCTCCTGGACAGACTAAAGCCACCCCTTGCA 1430
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1538 AGCCCTGGGCTAGGAGGGCCCCTGGGAAGCCTCCTGGACAGACTAAAGCCACCCCTTGCA 1597

Qy      1431 GATGGGGAGGACTGGGCTGGGGGACTGCCCTGGGGTGGCCGGTCACCTGGAGGGGTCTCA 1490
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1598 GATGGGGAGGACTGGGCTGGGGGACTGCCCTGGGGTGGCCGGTCACCTGGAGGGGTCTCA 1657

Qy      1491 GAGAGTGAGGCGGGCTCACCCCTGGCCGGCCTGGATATGGACACGTTTGACAGTGGCTTT 1550
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1658 GAGAGTGAGGCGGGCTCACCCCTGGCCGGCCTGGATATGGACACGTTTGACAGTGGCTTT 1717

Qy      1551 GTGGGCTCTGACTGCAGCAGCCCTGTGGAGTGTGACTTCACCAGCCCCGGGGACGAAGGA 1610
```

Applicant's copy Appendix A8

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1718 GTGGGCTCTGACTGCAGCAGCCCTGTGGAGTGTGACTTCACCAGCCCCGGGGACGAAGGA 1777

Qy       1611 CCCCCCCGGAGCTACCTCCGCCAGTGGGTGGTCATTCCTCCGCCACTTTCGAGCCCTGGA 1670
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1778 CCCCCCCGGAGCTACCTCCGCCAGTGGGTGGTCATTCCTCCGCCACTTTCGAGCCCTGGA 1837

Qy       1671 CCCCAGGCCAGCTAATGAGGCTGACTGGATGTCCAGAGCTGGCCAGGCCACTGGGCCCTG 1730
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1838 CCCCAGGCCAGCTAATGAGGCTGACTGGATGTCCAGAGCTGGCCAGGCCACTGGGCCCTG 1897

Qy       1731 AGCCAGAGACAAGGTCACCTGGGCTGTGATGTGAAGACACCTGCAGCCTTTGGTCTCCTG 1790
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1898 AGCCAGAGACAAGGTCACCTGGGCTGTGATGTGAAGACACCTGCAGCCTTTGGTCTCCTG 1957

Qy       1791 GATGGGCCTTTGAGCCTGATGTTTACAGTGTCTGTGTGTGTGTGTGCATATGTGTGTGTG 1850
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1958 GATGGGCCTTTGAGCCTGATGTTTACAGTGTCTGTGTGTGTGTGTGCATATGTGTGTGTG 2017

Qy       1851 TGCATATGCATGTGTGTGTGTGTGTGTCTTAGGTGCGCAGTGGCATGTCCACGTGTGT 1910
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2018 TGCATATGCATGTGTGTGTGTGTGTGTCTTAGGTGCGCAGTGGCATGTCCACGTGTGT 2077

Qy       1911 GTGTGATTGCACGTGCCTGTGGGCCTGGGATAATGCCCATGGTACTCCATGCATTCACCT 1970
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2078 GTGTGATTGCACGTGCCTGTGGGCCTGGGATAATGCCCATGGTACTCCATGCATTCACCT 2137

Qy       1971 GCCCTGTGCATGTCTGGACTCACGGAGCTCACCCATGTGCACAAGTGTGCACAGTAAACG 2030
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2138 GCCCTGTGCATGTCTGGACTCACGGAGCTCACCCATGTGCACAAGTGTGCACAGTAAACG 2197

Qy       2031 TGTTTGTGGTCAACAGATGACAACAGCCGTCCTCCCTCCTAGGGTCTTGTGTTGCAAGTT 2090
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2198 TGTTTGTGGTCAACAGATGACAACAGCCGTCCTCCCTCCTAGGGTCTTGTGTTGCAAGTT 2257

Qy       2091 GGTCCACAGCATCTCCGGGGCTTTGTGGGATCAGGGCATTGCCTGTGACTGAGGCGGAGC 2150
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2258 GGTCCACAGCATCTCCGGGGCTTTGTGGGATCAGGGCATTGCCTGTGACTGAGGCGGAGC 2317

Qy       2151 CCAGCCCTCCAGCGTCTGCCTCCAGGAGCTGCAAGAAGTCCATATTGTTCCTTATCACCT 2210
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2318 CCAGCCCTCCAGCGTCTGCCTCCAGGAGCTGCAAGAAGTCCATATTGTTCCTTATCACCT 2377

Qy       2211 GCCAACAGGAAGCGAAAGGGGATGGAGTGAGCCCATGGTGACCTCGGGAATGGCAATTTT 2270
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2378 GCCAACAGGAAGCGAAAGGGGATGGAGTGAGCCCATGGTGACCTCGGGAATGGCAATTTT 2437

Qy       2271 TTGGGCGGCCCCTGGACGAAGGTCTGAATCCCGACTCTGATACCTTCTGGCTGTGCTACC 2330
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2438 TTGGGCGGCCCCTGGACGAAGGTCTGAATCCCGACTCTGATACCTTCTGGCTGTGCTACC 2497

Qy       2331 TGAGCCAAGTCGCCTCCCCTCTCTGGGCTAGAGTTTCCTTATCCAGACAGTGGGGAAGGC 2390
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2498 TGAGCCAAGTCGCCTCCCCTCTCTGGGCTAGAGTTTCCTTATCCAGACAGTGGGGAAGGC 2557

Qy       2391 ATGACACACCTGGGGGAAATTGGCGATGTCACCCGTGTACGGTACGCAGCCCAGAGCAGA 2450
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2558 ATGACACACCTGGGGGAAATTGGCGATGTCACCCGTGTACGGTACGCAGCCCAGAGCAGA 2617

Qy       2451 CCCTCAATAAACGTCAGCTTCCTTC 2475
                |||||||||||||||||||||||||
```

Appendix A5 Applicant's copy

```
Db       2618 CCCTCAATAAACGTCAGCTTCCTTC 2642


RESULT 6
US-09-949-016-17415
; Sequence 17415, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
;  APPLICANT: VENTER, J. Craig et al.
;  TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
;  TITLE OF INVENTION:  WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
;  FILE REFERENCE: CL001307
;  CURRENT APPLICATION NUMBER: US/09/949,016
;  CURRENT FILING DATE:  2000-04-14
;  PRIOR APPLICATION NUMBER: 60/241,755
;  PRIOR FILING DATE: 2000-10-20
;  PRIOR APPLICATION NUMBER: 60/237,768
;  PRIOR FILING DATE: 2000-10-03
;  PRIOR APPLICATION NUMBER: 60/231,498
;  PRIOR FILING DATE: 2000-09-08
;  NUMBER OF SEQ ID NOS: 207012
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 17415
;   LENGTH: 27184
;   TYPE: DNA
;   ORGANISM: Human
US-09-949-016-17415

  Query Match             67.1%;  Score 1935.8;  DB 3;  Length 27184;
  Best Local Similarity   99.5%;  Pred. No. 0;
  Matches 1952;  Conservative    0;  Mismatches    7;  Indels    2;  Gaps    1;

Qy        929 CTTCAAGAAATGGGTGGGTGCACCCTTCACTGGCTCCAGCCTGGAGCTGGGACCCTGGAG 988
              ||   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      23223 CTCACAGAAATGGGTGGGTGCACCCTTCACTGGCTCCAGCCTGGAGCTGGGACCCTGGAG 23282

Qy        989 CCCAGAGGTGCCCTCCACCCTGGAGGTGTACAGCTGCCACCCACCACGGAGCCCGGCCAA 1048
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      23283 CCCAGAGGTGCCCTCCACCCTGGAGGTGTACAGCTGCCACCCACCACGGAGCCCGGCCAA 23342

Qy       1049 GAGGCTGCAGCTCACGGAGCTACAAGAACCAGCAGAGCTGGTGGAGTCTGACGGTGTGCC 1108
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      23343 GAGGCTGCAGCTCACGGAGCTACAAGAACCAGCAGAGCTGGTGGAGTCTGACGGTGTGCC 23402

Qy       1109 CAAGCCCAGCTTCTGGCCGACAGCCCAGAACTCGGGGGGCTCAGCTTACAGTGAGGAGAG 1168
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      23403 CAAGCCCAGCTTCTGGCCGACAGCCCAGAACTCGGGGGGCTCAGCTTACAGTGAGGAGAG 23462

Qy       1169 GGATCGGCCATACGGCCTGGTGTCCATTGACACAGTGACTGTGCTAGATGCAGAGGGGCC 1228
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      23463 GGATCGGCCATACGGCCTGGTGTCCATTGACACAGTGACTGTGCTAGATGCAGAGGGGCC 23522

Qy       1229 ATGCACCTGGCCCTGCAGCTGTGAGGATGACGGCTACCCAGCCCTGGACCTGGATGCTGG 1288
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      23523 ATGCACCTGGCCCTGCAGCTGTGAGGATGACGGCTACCCAGCCCTGGACCTGGATGCTGG 23582

Qy       1289 CCTGGAGCCCAGCCCAGGCCTAGAGGACCCACTCTTGGATGCAGGGACCACAGTCCTGTC 1348
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      23583 CCTGGAGCCCAGCCCAGGCCTAGAGGACCCACTCTTGGATGCAGGGACCACAGTCCTGTC 23642

Qy       1349 CTGTGGCTGTGTCTCAGCTGGCAGCCCTGGGCTAGGAGGGCCCCTGGGAAGCCTCCTGGA 1408
```

Appendix B1 Applicants copy

```
Db       1261 GCAGGGACCACAGTCCTGTCCTGTGGCTGTGTCTCAGCTGGCAGCCCTGGGCTAGGAGGG 1320

Qy        441 ProLeuGlySerLeuLeuAspArgLeuLysProProLeuAlaAspGlyGluAspTrpAla 460
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1321 CCCCTGGGAAGCCTCCTGGACAGACTAAAGCCACCCCTTGCAGATGGGGAGGACTGGGCT 1380

Qy        461 GlyGlyLeuProTrpGlyGlyArgSerProGlyGlyValSerGluSerGluAlaGlySer 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1381 GGGGGACTGCCCTGGGGTGGCCGGTCACCTGGAGGGGTCTCAGAGAGTGAGGCGGGCTCA 1440

Qy        481 ProLeuAlaGlyLeuAspMetAspThrPheAspSerGlyPheValGlySerAspCysSer 500
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1441 CCCCTGGCCGGCCTGGATATGGACACGTTTGACAGTGGCTTTGTGGGCTCTGACTGCAGC 1500

Qy        501 SerProValGluCysAspPheThrSerProGlyAspGluGlyProProArgSerTyrLeu 520
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1501 AGCCCTGTGGAGTGTGACTTCACCAGCCCCGGGGACGAAGGACCCCCCCGGAGCTACCTC 1560

Qy        521 ArgGlnTrpValValIleProProProLeuSerSerProGlyProGlnAlaSer 538
              ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1561 CGCCAGTGGGTGGTCATTCCTCCGCCACTTTCGAGCCCTGGACCCCAGGCCAGC 1614

RESULT 6
US-09-040-005-1
; Sequence 1, Application US/09040005
; Patent No. 6057128
;  GENERAL INFORMATION:
;    APPLICANT:  Donaldson, Debra
;    APPLICANT:  Unger, Michelle
;    TITLE OF INVENTION:  MU-1 RECEPTOR
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Genetics Institute, Inc.
;      STREET:  87 CmabridgePark Drive
;      CITY:  Cambridge
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02140
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/040,005
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Brown, Scott A
;      REGISTRATION NUMBER:  32,724
;      REFERENCE/DOCKET NUMBER:  GI5320
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-498-8224
;      TELEFAX:  617-876-5851
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  2665 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
```

Appendix B2 Application

US-09-040-005-1

Alignment Scores:

Pred. No.:	1.32e-249	Length:	2665
Score:	2958.00	Matches:	538
Percent Similarity:	100.0%	Conservative:	0
Best Local Similarity:	100.0%	Mismatches:	0
Query Match:	100.0%	Indels:	0
DB:	3	Gaps:	0

US-10-715-998-2 (1-538) x US-09-040-005-1 (1-2665)

```
Qy          1 MetProArgGlyTrpAlaAlaProLeuLeuLeuLeuLeuGlnGlyGlyTrpGlyCys 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        236 ATGCCGCGTGGCTGGGCCGCCCCCTTGCTCCTGCTGCTGCTCCAGGGAGGCTGGGGCTGC 295

Qy         21 ProAspLeuValCysTyrThrAspTyrLeuGlnThrValIleCysIleLeuGluMetTrp 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        296 CCCGACCTCGTCTGCTACACCGATTACCTCCAGACGGTCATCTGCATCCTGGAAATGTGG 355

Qy         41 AsnLeuHisProSerThrLeuThrLeuThrTrpGlnAspGlnTyrGluGluLeuLysAsp 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        356 AACCTCCACCCCAGCACGCTCACCCTTACCTGGCAAGACCAGTATGAAGAGCTGAAGGAC 415

Qy         61 GluAlaThrSerCysSerLeuHisArgSerAlaHisAsnAlaThrHisAlaThrTyrThr 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        416 GAGGCCACCTCCTGCAGCCTCCACAGGTCGGCCCACAATGCCACGCATGCCACCTACACC 475

Qy         81 CysHisMetAspValPheHisPheMetAlaAspAspIlePheSerValAsnIleThrAsp 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        476 TGCCACATGGATGTATTCCACTTCATGGCCGACGACATTTTCAGTGTCAACATCACAGAC 535

Qy        101 GlnSerGlyAsnTyrSerGlnGluCysGlySerPheLeuLeuAlaGluSerIleLysPro 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        536 CAGTCTGGCAACTACTCCCAGGAGTGTGGCAGCTTTCTCCTGGCTGAGAGCATCAAGCCG 595

Qy        121 AlaProProPheAsnValThrValThrPheSerGlyGlnTyrAsnIleSerTrpArgSer 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        596 GCTCCCCCTTTCAACGTGACTGTGACCTTCTCAGGACAGTATAATATCTCCTGGCGCTCA 655

Qy        141 AspTyrGluAspProAlaPheTyrMetLeuLysGlyLysLeuGlnTyrGluLeuGlnTyr 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        656 GATTACGAAGACCCTGCCTTCTACATGCTGAAGGGCAAGCTTCAGTATGAGCTGCAGTAC 715

Qy        161 ArgAsnArgGlyAspProTrpAlaValSerProArgArgLysLeuIleSerValAspSer 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        716 AGGAACCGGGGAGACCCCTGGGCTGTGAGTCCGAGGAGAAAGCTGATCTCAGTGGACTCA 775

Qy        181 ArgSerValSerLeuLeuProLeuGluPheArgLysAspSerSerTyrGluLeuGlnVal 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        776 AGAAGTGTCTCCCTCCTCCCCCTGGAGTTCCGCAAAGACTCGAGCTATGAGCTGCAGGTG 835

Qy        201 ArgAlaGlyProMetProGlySerSerTyrGlnGlyThrTrpSerGluTrpSerAspPro 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        836 CGGGCAGGGCCCATGCCTGGCTCCTCCTACCAGGGGACCTGGAGTGAATGGAGTGACCCG 895

Qy        221 ValIlePheGlnThrGlnSerGluGluLeuLysGluGlyTrpAsnProHisLeuLeuLeu 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        896 GTCATCTTTCAGACCCAGTCAGAGGAGTTAAAGGAAGGCTGGAACCCTCACCTGCTGCTT 955

Qy        241 LeuLeuLeuLeuValIleValPheIleProAlaPheTrpSerLeuLysThrHisProLeu 260
```

Appendix B3 Applicant copy

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        956 CTCCTCCTGCTTGTCATAGTCTTCATTCCTGCCTTCTGGAGCCTGAAGACCCATCCATTG 1015

Qy        261 TrpArgLeuTrpLysLysIleTrpAlaValProSerProGluArgPhePheMetProLeu 280
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1016 TGGAGGCTATGGAAGAAGATATGGGCCGTCCCCAGCCCTGAGCGGTTCTTCATGCCCCTG 1075

Qy        281 TyrLysGlyCysSerGlyAspPheLysLysTrpValGlyAlaProPheThrGlySerSer 300
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1076 TACAAGGGCTGCAGCGGAGACTTCAAGAAATGGGTGGGTGCACCCTTCACTGGCTCCAGC 1135

Qy        301 LeuGluLeuGlyProTrpSerProGluValProSerThrLeuGluValTyrSerCysHis 320
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1136 CTGGAGCTGGGACCCTGGAGCCCAGAGGTGCCCTCCACCCTGGAGGTGTACAGCTGCCAC 1195

Qy        321 ProProArgSerProAlaLysArgLeuGlnLeuThrGluLeuGlnGluProAlaGluLeu 340
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1196 CCACCACGGAGCCCGGCCAAGAGGCTGCAGCTCACGGAGCTACAAGAACCAGCAGAGCTG 1255

Qy        341 ValGluSerAspGlyValProLysProSerPheTrpProThrAlaGlnAsnSerGlyGly 360
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1256 GTGGAGTCTGACGGTGTGCCCAAGCCCAGCTTCTGGCCGACAGCCCAGAACTCGGGGGGC 1315

Qy        361 SerAlaTyrSerGluGluArgAspArgProTyrGlyLeuValSerIleAspThrValThr 380
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1316 TCAGCTTACAGTGAGGAGAGGGATCGGCCATACGGCCTGGTGTCCATTGACACAGTGACT 1375

Qy        381 ValLeuAspAlaGluGlyProCysThrTrpProCysSerCysGluAspAspGlyTyrPro 400
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1376 GTGCTAGATGCAGAGGGGCCATGCACCTGGCCCTGCAGCTGTGAGGATGACGGCTACCCA 1435

Qy        401 AlaLeuAspLeuAspAlaGlyLeuGluProSerProGlyLeuGluAspProLeuLeuAsp 420
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1436 GCCCTGGACCTGGATGCTGGCCTGGAGCCCAGCCCAGGCCTAGAGGACCCACTCTTGGAT 1495

Qy        421 AlaGlyThrThrValLeuSerCysGlyCysValSerAlaGlySerProGlyLeuGlyGly 440
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1496 GCAGGGACCACAGTCCTGTCCTGTGGCTGTGTCTCAGCTGGCAGCCCTGGGCTAGGAGGG 1555

Qy        441 ProLeuGlySerLeuLeuAspArgLeuLysProProLeuAlaAspGlyGluAspTrpAla 460
```

start | next page

SCORE 1.3 BuildDate: 11/17/2006

Appears B4 Application wrong

SCORE Search Results Details for Application 107 and Search Result $itemName.

Score Home Page Retrieve Application List SCORE System Overview SCORE FAQ Comments / Sugg

This page gives you Search Results detail for the Application 10715998 and Search Result $itemNa

start | next page

Go Back to

```
                      ||||||||||||||||||||||||||||||||||||||||||||||||
Db       1556 CCCCTGGGAAGCCTCCTGGACAGACTAAAGCCACCCCTTGCAGATGGGGAGGACTGGGCT 1615

Qy        461 GlyGlyLeuProTrpGlyGlyArgSerProGlyGlyValSerGluSerGluAlaGlySer 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1616 GGGGGACTGCCCTGGGGTGGCCGGTCACCTGGAGGGGTCTCAGAGAGTGAGGCGGGCTCA 1675

Qy        481 ProLeuAlaGlyLeuAspMetAspThrPheAspSerGlyPheValGlySerAspCysSer 500
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1676 CCCCTGGCCGGCCTGGATATGGACACGTTTGACAGTGGCTTTGTGGGCTCTGACTGCAGC 1735

Qy        501 SerProValGluCysAspPheThrSerProGlyAspGluGlyProProArgSerTyrLeu 520
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1736 AGCCCTGTGGAGTGTGACTTCACCAGCCCCGGGGACGAAGGACCCCCCCGGAGCTACCTC 1795

Qy        521 ArgGlnTrpValValIleProProProLeuSerSerProGlyProGlnAlaSer 538
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1796 CGCCAGTGGGTGGTCATTCCTCCGCCACTTTCGAGCCCTGGACCCCAGGCCAGC 1849

RESULT 7
US-09-404-641-1
; Sequence 1, Application US/09404641
; Patent No. 6576744
; GENERAL INFORMATION:
;  APPLICANT: Presnell, Scott R.
;  APPLICANT:  Conklin, Darrell C.
;  APPLICANT:  No. 6576744ak, Julia E.
;  APPLICANT:  Hammond, Angela K.
;  TITLE OF INVENTION: CYTOKINE RECEPTOR ZAPLHA11
;  FILE REFERENCE: 98-55
;  CURRENT APPLICATION NUMBER: US/09/404,641
;  CURRENT FILING DATE:  1999-09-23
;  PRIOR APPLICATION NUMBER: US 60/100,896
;  PRIOR FILING DATE: 1998-09-23
;  PRIOR APPLICATION NUMBER: US 60/123,546
;  PRIOR FILING DATE: 1999-03-09
;  PRIOR APPLICATION NUMBER: US 60/142,574
;  PRIOR FILING DATE: 1999-07-06
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1
;   LENGTH: 2887
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: CDS
;   LOCATION: (69)...(1682)
US-09-404-641-1
```